Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Acquisitions

25 Oct 2023 07:00

RNS Number : 1552R
Halma PLC
25 October 2023
 

Halma plc ('Halma' or the 'Group')

Acquisitions

Halma, the global group of life-saving technology companies, today announces that it has completed two bolt-on acquisitions for an aggregate maximum total consideration of approximately £46.5m.

 

In the Environmental and Analysis sector, Halma company, Alicat Scientific, Inc. (Alicat), has acquired the Alpha Instrumatics Group (Alpha Instrumatics).

 

Based in Bradford, UK, Alpha Instrumatics designs and manufactures devices for high-precision measurement of trace moisture found in gases. Trace moisture analysis allows the safer operation of industrial equipment, more efficient transfer of hydrocarbons, and more accurate detection of pollutants. Alpha Instrumatics' devices are used in growth markets, including the industrial gas and aerospace markets, as well as industries aligned to the new energy transition. This acquisition extends Alicat's product offering in its existing and adjacent end markets.

 

The initial cash consideration for Alpha Instrumatics is £31m, on a cash- and debt-free basis, which will be funded from Halma's existing facilities. Additional earn-out considerations are payable in cash, based on its performance over each of the two financial years to 31 March 2025, up to an aggregate maximum of £5.5m. Alpha Instrumatics' consolidated unaudited revenue for the 12 months to 30 September 2023 was £7.8m, with Return on Sales substantially above the upper end of Halma's target range of 18-22%.

 

In the Healthcare sector, Halma company, IZI Medical Products LLC (IZI), has acquired AprioMed AB (AprioMed). AprioMed designs, manufactures and distributes medical devices used for bone biopsies. This acquisition expands IZI's offerings for minimally invasive procedures, complementing its products used to diagnose and treat cancer.

 

The consideration for AprioMed is SEK130m (approximately £10m) on a cash- and debt-free basis, which is funded from Halma's existing facilities. AprioMed's unaudited revenue for the 12 months to 31 March 2023 was SEK40.0 (approximately £3.0m), with Return on Sales above Halma's target range of 18-22%.

Marc Ronchetti, Group Chief Executive of Halma, commented:

 

"Our companies have access to Halma expertise and capital to support their growth locally and internationally. These bolt-on acquisitions are strongly aligned with our purpose and financial model and will bring complementary capabilities to Alicat and IZI Medical, including new technologies and broader market reach. We are excited by the opportunities we see for new standalone companies to join Halma and for our existing companies to add new capabilities through bolt-on acquisitions to grow their businesses over the long term."

 

For further information, please contact:

Halma plc

Marc Ronchetti, Group Chief Executive +44 (0)1494 721111

Steve Gunning, Group Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare +44 (0)20 3128 8100 

A copy of this announcement, together with other information about Halma, is available at www.halma.com.

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three broad markets it operates in:

· Safety - Protecting people's safety and the environment as populations grow, and enhancing worker safety.

· Environment - Addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.

· Health - Meeting the increasing demand for better healthcare as chronic illness rises, driven by growing and ageing populations and lifestyle changes.

It employs over 8,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past five years.

For more information www.halma.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUSSVROWURUAA
Date   Source Headline
5th Jul 20064:14 pmRNSAnnual Report and Accounts
5th Jul 20064:11 pmRNSHolding(s) in Company
30th Jun 20061:25 pmRNSHolding(s) in Company
30th Jun 20061:19 pmRNSHolding(s) in Company
30th Jun 20068:55 amRNSDirector/PDMR Shareholding
27th Jun 20069:58 amRNSTreasury Stock
21st Jun 200610:18 amRNSHolding(s) in Company
20th Jun 20067:01 amRNSFinal Results
19th Jun 200611:22 amRNSSector change
15th Jun 200610:56 amRNSAdditional Listing
9th Jun 20061:41 pmRNSHolding(s) in Company
5th Jun 200611:54 amRNSNotice of Board Meeting
30th May 20063:45 pmRNSHolding(s) in Company
18th May 20064:04 pmRNSHolding(s) in Company
9th May 20063:02 pmRNSHolding(s) in Company
5th May 200612:21 pmRNSHolding(s) in Company
27th Apr 20067:00 amRNSTrading Statement
18th Apr 20067:01 amRNSAcquisition
30th Mar 20061:40 pmRNSShare Plan Treasury Shares
23rd Mar 200610:36 amRNSDirector/PDMR Shareholding
16th Mar 20062:15 pmRNSHolding(s) in Company
15th Mar 200612:49 pmRNSDirector/PDMR Shareholding
14th Mar 200610:32 amRNSHolding(s) in Company
13th Mar 200611:18 amRNSSAR 5 - (Halma PLC)
6th Mar 20062:53 pmRNSHolding(s) in Company
3rd Mar 20061:49 pmRNSHolding(s) in Company
3rd Mar 20069:50 amRNSSAR 5 - Halma plc
28th Feb 20067:01 amRNSDisposal and trading update
16th Feb 200612:48 pmRNSHolding(s) in Company
1st Feb 20061:54 pmRNSHolding(s) in Company
1st Feb 200611:01 amRNSSAR 5 - Halma plc
27th Jan 200611:51 amRNSBlocklisting Interim Review
11th Jan 20062:05 pmRNSDirector/PDMR Shareholding
9th Jan 20064:30 pmRNSHolding(s) in Company
9th Jan 200612:27 pmRNSHolding(s) in Company
4th Jan 20064:47 pmRNSHolding(s) in Company
6th Dec 200512:13 pmRNSDoc re. Interim Report 2005
6th Dec 20057:00 amRNSInterim Results
28th Nov 200512:26 pmRNSNew Reporting Sectors
21st Nov 20053:09 pmRNSNotice of Results
9th Nov 20057:00 amRNSAcquisition
27th Oct 20057:00 amRNSTrading Statement
19th Oct 20052:39 pmRNSAdditional Listing
13th Oct 20052:50 pmRNSDirector Declaration
27th Sep 20059:17 amRNSDirector/PDMR Shareholding
23rd Sep 20053:13 pmRNSDirector/PDMR Shareholding
9th Sep 20054:41 pmRNSHolding(s) in Company
2nd Sep 20057:00 amRNSAdoption of IFRS
12th Aug 20059:32 amRNSDirector/PDMR Shareholding
11th Aug 20059:15 amRNSAcquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.